--- title: "Unbranded search was paying for traffic the brand site already won" description: "Disease awareness and branded campaigns overlapped, double buying the same high intent visitor. Marketing & margin audit: $78k/yr in wasted spend cut." url: https://marginfix.ai/cases/unbranded-search-was-paying-for-traffic-the-brand-site-alrea/ lastmod: 2026-10-24 --- Unbranded search was paying for traffic the brand site already won. [Request an audit →](/book/) Pharma · Rx brand (DTC) # Unbranded search was paying for traffic the brand site already won. This marketing & margin audit identified **$78k in wasted annual spend** in a Pharma business, evidenced, senior reviewed, and delivered in 7 days. $3–8M annual revenue Rx brand (DTC) Focus: Search overlap −$78k wasted spend cut / yr −29% duplicate search spend 7 days to findings High intent visitors paid for twice Before audit ~1 in 3 → After fix ~1 in 30 ## The business An Rx pharmaceutical brand ran disease awareness (unbranded) search and branded search in parallel, with the two programs managed by different teams that rarely coordinated. Each team optimized and reported on its own campaigns separately, so while both looked reasonable in isolation, no one held a combined view of how the two efforts interacted across the same search landscape. ## What triggered the audit Combined search spend across the two programs was high, and because the teams reported independently, any overlap between them was structurally invisible. The audit examined both accounts together for the first time, testing whether unbranded and branded search were reaching genuinely different users or quietly competing for the same ones. ## What the audit found Viewed together, the two programs were substantially buying the same people twice. The unbranded, disease awareness campaigns were meant to reach early stage, uninformed audiences, but in practice a large share of the high intent visitors they captured were users the branded site would have won anyway through its own strong organic and branded presence. So the brand was paying twice to reach a single high intent visitor, once through unbranded search and again through branded, with the two teams each claiming their share and neither aware of the duplication. Because performance was only ever reviewed within each program, the overlap never surfaced. Netted across the year, this double buying of the same audience cost roughly $78k in avoidable, duplicated search spend. ◉ How we produced this finding MarginFix pressure tested the search overlap finding the same way it does for every pharma client: isolate what the spend actually caused, strip out what it merely took credit for, and let a named senior auditor validate the read against real data before a single figure is presented. Data sources: Spend by channel, campaign, creative and audience, joined to conversion and revenue data, plus a geo holdout test built to isolate what search overlap genuinely caused rather than what it merely claimed. Key frameworks: Geo holdout incrementality testing, Marketing Mix Modeling (MMM) and attribution correction and inflation factor analysis, cross checked against Analytic Partners ROI Genome, Google Meridian and Meta Robyn. Human validation gate: Every incrementality read is rerun against your own data and signed off by a named senior auditor before it ships. No automated output ever leaves the building unreviewed. Verified against CRM / rep call logs Search term reports Sample distribution records Territory spend ledger Finance P&L The wasted spend cut / yr was measured like for like over a matched period, reconciled to territory spend in the finance ledger, and signed off by a named senior auditor before publication. Client identity redacted to protect their commercial position. WORKING PAPER ████████ Rx brand (DTC) Representative Redacted Search theme Duplicated high intent Disease awareness 6% Symptom terms 12% Branded × unbranded overlap 33% wasted spend cut / yr +$77,650 Recurring, recovered every year the fix holds, not a one off. Working paper: high intent visitors paid for twice traced line by line and reconciled to territory spend in the finance ledger over a matched period. Line items representative and redacted; the recovered figure is the reconciled audit finding. ## What we changed ✓ Deconflicted unbranded and branded search with shared negative keywords and audience exclusions, so the two programs stop capturing the same high intent visitor twice. ✓ Unified both teams' bidding under a single coordinated plan spanning the full search landscape, ending the parallel purchasing of identical demand. ✓ Appointed one cross team search owner to keep the two accounts from quietly drifting back into overlap as they’re optimized over time. ✓ Reallocated the recovered spend toward the genuinely early stage, uninformed audiences the unbranded program was actually created to reach. ## The result The outcomes were measured for three months after a 90 day implementation period. $78k a year recovered by stopping two teams from buying the same visitor twice, an annual figure equal to 13× the $5,950 Audit + Sprint fee. For any pharma marketing lead, the structure caused the leak: unbranded and branded search reported separately, so the overlap was invisible to both. If your search programs run in silos, you may be paying twice for high intent visitors you’d win once anyway. Only looking across both accounts at once reveals it. A fixed fee audit does that in days and turns two competing programs into one coordinated engine capturing the same demand for far less. From kickoff to signed off findings: 7 days. ![Portrait photograph of Leslie Martin](/assets/team/leslie-martin.jpg) Reviewed & signed off by: Leslie Martin Senior Auditor · MarginFix · 10+ years of auditing experience ✓ Anonymized to protect the client · senior reviewed findings · Audit completed between 2024 and 2026, contracted through Cristian Bragau's practice before the MarginFix name existed · Published in the MarginFix library July 21, 2026 · Last reviewed October 24, 2026 ## What the client said PHARMA $78k a year of wasted spend cut in 7 days High intent visitors paid for twice: **~1 in 3 → ~1 in 30** “Two teams, two search programs, one visitor bought twice. Leslie looked at branded and disease awareness search together for the first time: about one high intent visitor in three was paid for twice. Shared negatives and one plan ended it.” **VP of Marketing · Pharma · Rx brand (DTC)** Written approval Under NDA 7 days to findings ![Portrait photograph of Leslie Martin](/assets/team/leslie-martin.jpg) **Leslie Martin** Senior Auditor · signed this audit off [Request an audit →](/book/) [Prefer to talk it through first? Talk to an auditor →](/book/call/) ## More Pharma findings [HCP and patient budgets were optimized in isolation, −$64k/yr](/cases/hcp-and-patient-budgets-were-optimised-in-isolation/) [Subscription acquisition ignored regulatory driven churn, +$44k/yr](/cases/subscription-acquisition-ignored-regulatory-driven-churn/) [Detailing and sample spend produced no prescribing lift, −$64k/yr](/cases/detailing-and-sample-spend-produced-no-prescribing-lift/) [Media ran outside the eligible population windows, −$58k/yr](/cases/media-ran-outside-the-eligible-population-windows/) [Retail vet channel discounts were set below margin, +$49k/yr](/cases/retail-vet-channel-discounts-were-set-below-margin/) [Patient acquisition spend ran above what reimbursement paid, −$71k/yr](/cases/patient-acquisition-spend-ran-above-what-reimbursement-paid/) [The benchmark: what audits recover across 74 cases →](/benchmark/) [All case studies](/case-studies/) [Model a Pharma budget in the wasted ad spend calculator →](/estimator/pharma/)